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Abstract objectives To estimate out-of-pocket (OOP) expenditure due to hospitalisation from NCDs and its
impact on households in India.
methods The study analysed nationwide representative data collected by the National Sample
Survey Organisation in 2014 that reported health service utilisation and healthcare-related OOP
expenditure by income quintiles and by type of health facility (public or private). The recall period
for inpatient hospitalisation expenditure was 365 days. Consumption expenditure was collected for a
recall period of 1 month. OOP expenditure amounting to >10% of annual consumption expenditure
was termed as catastrophic. Weighted analysis was performed.
results The median expenditure per episode of hospitalisation due to NCDs was USD 149 – this
was ~3 times higher among the richest quintile compared to poorest quintile. There was a
significantly higher prevalence of catastrophic expenditure among the poorest quintile, more so for
cancers (85%), psychiatric and neurological disorders (63%) and injuries (63%). Mean private-sector
OOP hospitalisation expenditure was nearly five times higher than that in the public sector.
Medicines accounted for 40% and 27% of public- and private-sector OOP hospitalisation
expenditure, respectively.
conclusion Strengthening of public health facilities is required at community level for the
prevention, control and management of NCDs. Promotion of generic medicines, better availability of
essential drugs and possible subsidisation for the poorest quintile will be measures to consider to
reduce OOP expenditure in public-sector facilities.
keywords non-communicable diseases, injury, cancer, out-of-pocket expenditure, catastrophic
expenditure
Introduction
Non-communicable diseases (NCDs) are a major threat
to general health, productivity, development and eco-
nomic growth and account for 63% of annual global
deaths [1]. Most of these deaths are premature and pre-
ventable. The probability of dying during the most pro-
ductive years (ages 30–70) from one of the four main
NCDs [cancer, cardiovascular disease, diabetes mellitus
and stroke] is 26%. If urgent action is not taken, NCDs
could hurt economic growth and cause an estimated eco-
nomic loss of $47 trillion during the period 2010–30 [2].
In an ageing nation like India, an increase in the preva-
lence of NCDs is likely to put additional burdens on
households and the resource-constrained healthcare
delivery system. India runs the risk of losing about $4.6
trillion by 2030 due to NCDs and mental health condi-
tions. In 2010, NCDs accounted for more disability-
adjusted life years (DALYs) in India than communicable
diseases [2].
With a rising burden of NCDs, delivering health care
in developing countries has many challenges. Even when
such care is available, individuals with NCDs will con-
tinue to face significant risks of hospitalisation and the
associated burden of high costs of financing care. A
review of the literature shows that households spend a
substantial share of their income on health care leading
to catastrophic expenditure and impoverishment [3].
Each year, globally, approximately 150 million people in
44 million households face catastrophic expenditure and
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about 100 million people in 25 million households are
pushed into poverty because they have to pay for health
care [3].
The extent of the financial burden due to NCDs in
India is poorly researched [4, 5]. A gap area is the house-
hold impact of out-of-pocket (OOP) hospitalisation
expenditure due to NCDs. This information would be
helpful in formulating social protection strategies to
increase financial risk protection for households affected
with NCDs. With the rising burden of NCDs, we need to
look for answers whether people have access to the ser-
vices they need to prevent or control these diseases, and
the extent to which they suffer financial catastrophe or
impoverishment in accessing the services.
There have been a few studies in India analysing house-
hold expenditure on chronic illnesses either combined or
separately for diabetes, CVD and injuries [6–11]. How-
ever, these studies were limited to a specific geographical
area or a hospital with unrepresentative samples. Another
study by Engelgau et al. explored OOP for NCD care
and the risk of catastrophic payment in a nationally rep-
resentative survey sample [12] more than a decade ago.
Since then, there has been an unprecedented rise in the
burden of NCDs [13]. The public health infrastructure in
India has seen massive growth after significant invest-
ments through the National Health Mission since 2005
[14]. The private sector has also proliferated due to gov-
ernment apathy [15]. In the present scenario, we have
limited estimates of household expenditure patterns on
hospitalisation due to NCDs, both in the public and in
the private sector. Availability of National Sample Survey
Organisation (NSSO) data, from a nationally representa-
tive survey conducted in 2014, provided us an opportu-
nity to study this.
Therefore, this study was undertaken to estimate the
proportion of all hospitalisations in public-sector facilities
due to non-communicable diseases by income quintiles,
and the median out-of-pocket expenditure and prevalence
of catastrophic expenditure due to hospitalisation from
non-communicable disease by type of health facility and
income quintiles.
Methods
This is a secondary data analysis of a nationwide survey
data collected by the NSSO, India. The data source is the
representative nationwide survey collected by the National
Sample Survey Organisation (NSSO) in its 71st round
(2014) on ‘Health’ and ‘Education’. NSSO is a national
organisation under the Ministry of Statistics, established in
1950 to regularly conduct surveys and provide useful
statistics on socio-economic status of households,
demography, health, industries, agriculture, consumer
expenditure, etc. Results of NSSO surveys are published in
the form of NSS reports available at the website of the
ministry (www.mospi.nic.in). So far, there have been 71
rounds of surveys; the last (71st round) was carried out for
6 months from January to June 2014. A stratified multi-
stage sampling design was adopted. The first-stage units
were the census villages in the rural sector and Urban
Frame Survey (UFS) blocks in the urban sector. The ulti-
mate-stage units were households in both sectors. A total
of 4577 villages and 3720 urban blocks were surveyed,
from which 36 480 and 29 452 households were sampled
in rural and urban areas, respectively. In total, 333 104
persons from 65 932 households were interviewed.
Detailed methods can be found in the survey report [16].
OOP expenditure for each episode of hospitalisation
was recorded. Detailed expenditure was available for
drugs; diagnostic tests (including ECG, X-ray and patho-
logical tests); professional fees for doctors; payments to
hospital/institution; other medical expenses (physiother-
apy, personal medical appliances, blood, oxygen, atten-
dant charges, etc.); and other indirect costs. Indirect costs
included transport for patients and other accompanying
persons, food-related expenses, lodging charges and
others. Household consumption expenditure was
recorded as well as other socio-demographic characteris-
tics including caste, occupation, gender and education.
Data were also collected on type of facility (public or pri-
vate) accessed for medical care.
The recall period was 365 days for assessing inpatient
hospitalisation expenditure, and 1 month for household
consumption expenditure. OOP expenditure per hospital-
isation episode amounting to more than 10% of annual
consumption expenditure was termed as ‘catastrophic’
[17, 18].
Disease conditions in the household survey were self-
reported. We matched the categories in the surveys to
broad ICD-10 disease classifications to distinguish
between major NCD categories and communicable dis-
eases (Box 1).
Data analysis
Data were imported into SPSS version 17.0 for analysis
(SPSS Inc. SPSS Statistics for Windows, Version 17.0. Chi-
cago). The unit of analysis was an episode of hospitalisa-
tion. The study population was divided into quintile
groups based on monthly per capita consumption expendi-
ture (MPCE). The household monthly per capita consump-
tion expenditure limits (in USD) for the five quintiles are as
follows: the first quintile (2–16), second quintile (17–22),
third quintile (23–30), fourth quintile (31–46) and fifth
1020 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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quintile (47–538). Median values/percentages for all indi-
cators were compared across each of the five MPCE quin-
tiles and type of health facility (public and private).
Median hospitalisation expenditure per episode was esti-
mated for those who reported hospitalisation due to NCD.
The Kruskal–Wallis test was used to evaluate the statistical
significance of differences in expenditures between the
quintiles. Chi-square test for trend was used to test linear
trends across quintiles. As it was a multistage stratified ran-
dom survey, estimates were derived by applying sampling
weights given by the NSSO.
Ethical approval
The Ethics Advisory Group of International Union Against
Tuberculosis and Lung Disease, Paris, France, determined
that ethics clearance was not required for this study.
Results
Of a total of 57 456 hospitalisations, 25% were due to
NCDs, 22% to communicable diseases and 53% to other
conditions. A total of 11 843 subjects reported 14 609
episodes of hospitalisations due to non-communicable
disease in the last 365 days, of which 1.6% of episodes
were removed due to missing data. Among the cases of
hospitalisation due to NCDs, 31% were due to injuries;
25% to CVD; 18% to psychiatric/neurological condi-
tions; 9% to respiratory diseases; 8% to endocrine/meta-
bolic disorders; and 8% to cancers. 85% of respondents
reported one episode of hospitalisation in the previous
year; 11% reported two episodes and 4% reported more
than two episodes. 26% were females. The mean age of
the respondents was 49 years (SD = 16). The mean dura-
tion of hospitalisation was highest in cases of cancer
(15 days), followed by injuries and psychiatric/neurologi-
cal disorders (9 days), endocrine/metabolic diseases
(8 days) and CVD and respiratory diseases (7 days).
Hospitalisation-related expenditure due to NCDs
Median expenditure per episode of hospitalisation due to
NCDs was 149 USD. The expenditure incurred was ~3
times higher among the richest quintile than in the poor-
est quintile. There was a significantly higher prevalence
of catastrophic expenditure among the poorest quintile,
more pronounced with cancers (85%), psychiatric and
neurological disorders (63%) and injuries (63%)
(Table 1). Public-sector utilisation by the poorest quintile
was twice as common as by the richest quintile (Table 2).
The median private-sector OOP hospitalisation expendi-
ture was nearly 3–5 times higher than that of the public
sector due to various NCDs. Private-sector hospitalisation
expenditure was more than five times the public-sector
hospitalisation expenses in case of cardiovascular diseases
and injuries. Medicines accounted for 40% of public- and
27% of private-sector OOP hospitalisation expenditure. In
26% of hospitalisations, expenditures were sourced
through borrowing or sale of assets – this was significantly
higher among the poorest quintile (33%) than the richest
(19%), more common when care was sought in the private
sector (29%) than in the public sector (22%) and common
in case of cancer. Indirect costs were more than two times
higher in the public sector (24%) than in the private sector
(10%) (Table 3). Nearly 4.4% of respondents were
insured. Among the insured, median hospitalisation expen-
diture was significantly higher (USD 519) compared to the
non-insured (USD 160).
NCD-related hospitalisation leading to catastrophic
household expenditure
Hospitalisation due to an NCD had a three times higher
odds of incurring catastrophic spending than
Box 1 Classification of 2014 household survey
response categories from National Sample Survey
Organisation data into disease categories
Communicable diseases
Fever with rash/eruptive lesions, loss of consciousness
Fever due to malaria, typhoid, Diphtheria, Whooping
Cough, fevers of unknown origin)
Tuberculosis, Filariasis
Tetanus
HIV/AIDS and other Sexually Transmitted Diseases
Jaundice
Diarrhoea/dysentery/increased frequency of stools with or
without blood and mucus in stools
Worms infestation
Skin infection (boil, abscess, itching) and other skin
diseases
Acute upper respiratory infections
Non-communicable diseases
Cancers
Psychiatric and Neurological disorders
Endocrine, nutritional and metabolic disorders
Cardiovascular disorders
Chronic respiratory conditions (Bronchial asthma)
Injuries
Other conditions
Blood disorders
Disorders of the gastrointestinal system
Disorders of the genitourinary system
Obstetric complications
Disorders of eye and ear
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1021
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hospitalisation due to a communicable disease. For can-
cer, the impact was greatest with the odds of catastrophic
expenditures being 12 times higher than for hospital stays
due to a communicable disease (Table 4).
Discussion
The study shows that NCD-related expenditure per epi-
sode of hospitalisation in India is high and catastrophic
in among the poorest quintile. Cancers, psychiatric and
neurological disorders and injuries were the most expen-
sive. Expenditure was higher when care was accessed in
the private sector.
The utilisation of public facilities showed a pro-poor
distribution, which is corroborated by Shankar et al. who
also reported higher public-sector utilisation by the poor
in three states of North India [18]. This is an encouraging
sign considering the rising burden of NCDs. It lends sup-
port to the view that strengthening of the public health
system is instrumental in providing care for the rising epi-
demic of NCDs [19]. However, the results of the study
also showed that private care is very costly, which might
be the reason why poor people make greater use of pub-
lic care facilities. The proportion of hospital stays due to
NCDs in the public sector has remained stagnant at
around 41% since 2004 [12]. However, the use of public
services has decreased sharply with the increase in wealth
quintile class. Thus, people who are poor are heavily reli-
ant on public health facilities and are therefore most
affected by the unavailability of quality services in the
public sector.
About half of the patients belonging to the lowest two
quintiles approach the private sector for hospitalisation
due to NCDs. It is possible that patients with NCDs con-
sider their illness as serious requiring better services. So
despite their poor economic status, they might prefer
costlier private care. Also, there is a general scepticism
about quality of public health services [20, 21]. The full
survey report states the following reasons for not availing
government services: poor quality of care, long waiting
times, services not available or the facility too far. Thus,
the public sector needs to be strengthened in terms of
quality of care, infrastructure and availability of services,
providers and drugs to increase its access and utilisation.
With higher health spending under the National Rural
Health Mission, we may be on track.
Medicines accounted for 40% of public-sector OOP
hospitalisation expenditure which is significantly higher
than that in the private sector (27%). This supports a
large body of evidence showing that medicines form a
large component of the healthcare out-of-pocket expendi-
ture [6, 12, 22]. This finding is to be interpreted with
caution and does not mean that medicines are more
expensive in the public than in the private sector. Rather,
it means that as a percentage of total expenses, medicines
contribute the most in the public sector, while the abso-
lute costs remain lower than in the private sector. The
lower percentage of medicine costs in the private sector is
due to higher costs of other services (like diagnostic tests,
procedures and room rent) which are free or subsidised
in the public sector. Poor availability of essential medici-
nes for chronic diseases in public health facilities forces
patients to purchase medicines from the private sector
[23]. Thus, to increase access and affordability of health
care, promotion of generic medicines and improved avail-
ability of medicines and subsidisation of the poorest pop-
ulation quintiles in the public sector are required [24].
The Rajasthan model of a free-drug scheme has increased
access to health care for the underserved, reduced in
OOP and resulted in savings to the government [25]. A
drug pricing policy is needed to improve the availability
of affordable generics in the public sector, either by bet-
ter targeting of existing public spending for medicines or
by increasing the public budget on essential medicines.
Table 2 Utilisation of public-sector facilities for hospitalisation due to non-communicable diseases by income quintiles in India, 2014*
Income quintiles Cancer Endocrine/metabolic Psychiatric/neurological Cardiovascular Chronic respiratory Injuries Total
1st MPCE quintile 52 54 54 56 63 57 56
2nd MPCE quintile 46 42 48 45 61 46 47
3rd MPCE quintile 39 36 36 36 41 44 39
4th MPCE quintile 41 35 36 34 39 28 33
5th MPCE quintile 28 18 22 20 26 29 23
Overall 39 35 39 37 47 42 40
P-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
*Weighted analysis; MPCE, monthly per capita consumption expenditure; numbers given indicate percentage utilising public-sector
facility for hospitalisation due to non-communicable disease; the household monthly per capita consumption expenditure limits (in
USD) for the five quintiles are as follows: the first quintile (2–16), second quintile (17–22), third quintile (23–30), fourth quintile (31–
46) and fifth quintile (47–538).
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Cardiovascular disease is the largest cause of mortality
and accounted for more than one-fourth of all deaths in
India in 2008 [26]. Our study reveals prohibitive costs of
care due to CVD in the private sector, with one-fifth of
hospitalisations paid for by borrowings or sale of per-
sonal assets and medicines. The private sector is also typ-
ically driven by the use of advanced medical technology,
thus increasing the costs of diagnosis, care and treatment.
We speculate that there may be unnecessary (irrational)
overuse of such technology for increasing hospital activity
and profit margins by the private health sector. This mer-
its specific investigation. The issue of affordability is fur-
ther magnified by the low penetration of health insurance
in India. There is no coverage for preventive check-ups,
diagnosis or any medical care. Along with poor aware-
ness, this is a huge barrier towards lowering the burden
of CVDs through preventive measures.
Nearly 40% of those insured were prevented from
incurring catastrophic expenditure due to insurance pay-
ments. There is a need to mitigate this catastrophic
expenditure through prepayment risk pooling mecha-
nisms, such as social health insurance and tax-based
financing of health care. In practice, it has been found
that the beneficiaries of such programmes are often not
actually poor. Thus, packages should be redesigned to
target the poor and the disadvantaged. This study shows
that even after 6 years of implementation of Rashtriya
Swasthya Bima Yojana, a government social health insur-
ance scheme, there is a high prevalence of catastrophic
expenditure due to hospitalisation for NCDs in public-
sector facilities among the poorest quintiles. Considering
the long-term chronic care and repeated hospitalisations
for NCDs, separate customised insurance packages
should be designed for patients with this group of mor-
bidities. However, the median hospitalisation expenditure
among the insured was more than three times higher than
among the non-insured, which reflects moral hazards of
insurance requiring preventive mechanisms.
Hospitalisations due to injuries lead to a high preva-
lence of catastrophic OOP expenditure. There was also a
higher prevalence of OOP hospitalisation expenditures
being paid for by borrowing/debt/sale of assets in both
the public and private sectors. Other studies have also
outlined the high burden of OOP healthcare expenditure
associated with injuries in India [27, 28].
Apart from cancer, injury care leads to higher OOP
and impoverishment of households. Similarly, other stud-
ies have also reported higher OOP for injuries compared
with other diseases and ailments [29]. This might be due
to the fact that injuries requiring hospitalisations are
usually severe and lead to more fatalities and disabilities
[29]. Furthermore, the impact of injuries is sudden and
rapid requiring immediate hospitalisation, which
demands sophisticated emergency trauma care services
and prolonged duration of hospital stay. A review of
economic evidence in LMICs suggests that the direct
median medical cost of injury was US$291, which
increased 14-fold, that is US$4085, when studies
included direct medical, direct non-medical and indirect
costs [30]. This clearly shows the devastating financial
impact of injury on households. There is therefore a
need for advocacy for effective financial protection
mechanisms in India against high OOP expenditure
through insurance and universal health care. Various
Table 4 Adjusted odds ratios for catastrophic spending for patients with specific non-communicable diseases compared to those with
communicable diseases, India, 2014*
Type of disease
Type of expenditure
Unadjusted OR (95% CI) Adjusted OR (95% CI)Catastrophic† N (%)
Non-catastrophic
N (%)
Cancer 807 (74) 286 (26) 7.2‡ (6.2–8.2) 12.2‡ (12.0–12.4)
Endocrine/metabolic disorders 512 (42) 700 (58) 1.9‡ (1.6–2.1) 2.0‡ (1.9–2.1)
Psychiatric and neurological disorders 1410 (54) 1212 (46) 2.9‡ (2.7–3.2) 3.5‡ (3.2–3.8)
Cardiovascular diseases 1904 (53) 1720 (47) 2.8‡ (2.6–3.0) 2.8‡ (2.6–3.0)
Respiratory diseases 469 (37) 795 (63) 1.5‡ (1.3–1.7) 1.8‡ (1.6–2.0)
Injuries 2461 (55) 2044 (45) 3.0‡ (2.8–3.3) 3.2‡ (3.0–3.4)
Overall NCDs 7563 (53) 6757 (47) 2.8‡ (2.7–3.0) 3.0‡ (2.9.–3.1)
Communicable disease 3459 (28) 8781 (72) Reference§ Reference
*Weighted analysis; CI stands for confidence interval; OR stands for odds ratio.
†More than 10% of annual household consumption expenditure.
‡P-value <0.001; variables included in logit regression were age, sex, social group, education, income quintiles and type of health
facility.
§Reference category includes a list of communicable diseases as given in Box 1.
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1025
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cost-effective injury prevention strategies are established,
which include strict legislative measures to regulate vehi-
cle safety and road safety, installation of speed bumps,
motorcycle helmet and seat belt legislation, breath test-
ing campaigns and drowning prevention programmes.
Thus, in view of the high burden of injuries, high cost
of injury care and availability of cost-effective preventive
interventions, there is significant potential for huge cost
savings through implementation of established preventive
strategies [30].
There is high OOP hospitalisation expenditure related
to cancer care. The prevalence of catastrophic expendi-
ture is highest in those with cancers in all the quintiles,
but especially amongst the poorest. Cancer treatment in
private hospitals is expensive in India as evident from
other studies [31]. The high OOP expenditure due to can-
cer is sourced from borrowing/sale of assets in more than
one-third of patients [31]. The cost of cancer care is pro-
hibitive due to costly medicines, sophisticated equipment
and modern technology. Cancer also requires prolonged
period of hospitalisation as evident in this study. Provid-
ing cancer care free of cost at all public health facilities
would put an enormous financial burden on the health
system, but targeting the poorest quintile seems feasible
and equitable. Some state-level initiatives, such as the
Yashaswini health insurance scheme in Karnataka and
similar schemes in Andhra Pradesh and Tamil Nadu,
cover cancer treatment for people living below the pov-
erty line [31].
Current programmes that address cancer prevention,
care and treatment have not been effective due to limited
scale of implementation. It is imperative to strengthen
cancer control activities at the community with strong
prevention messages, early screening and proper manage-
ment as most of the common cancers are preventable
[32].
Our data confirm the important role that the private
sector currently plays in the provision of health services
for hospitalisations associated with NCDs. However, the
median OOP hospitalisation expenditure in the private
sector was 3–5 times higher than in the public sector. In
the last decade, there has been a significant increase in
private-sector expenditure on health care. During 2004–
2014, the out-of-pocket expenditure for inpatient care
per episode in the public sector diminished, whereas it
grew by 3.6% per year in the private sector [33]. This is
a reflection of the inability of the government to regulate
the private sector. The government needs to regulate the
private sector and at the same time use the private infras-
tructure to provide comprehensive preventive, promotive
and curative care services for NCDs that are accessible
and affordable.
Given that people living with NCDs face high risks of
catastrophic health expenditure due to the long-term nat-
ure of their illness and OOP payments, the health system
must provide universal access to quality health care,
reduce health inequities and improve financial risk pro-
tection through universal health coverage (UHC). Many
countries have already introduced NCD packages into
UHC programmes using frameworks developed by WHO
[34]. Thus, NCD prevention and control should be pri-
oritised in UHC design and implementation.
There are some limitations in this study. Firstly, con-
sumption expenditure in the survey does not differentiate
between food and non-food expenditure. WHO recom-
mends a 40% cut-off level for non-food expenditure [35].
In this study, we have used a threshold of 10% of annual
consumption expenditure. However, this does not pro-
vide an accurate estimate of catastrophic expenditure as
the expenditure on food as a proportion of total con-
sumption expenditure is higher for poorer households.
Hence, the results of the present study for catastrophic
expenditure may be an underestimate for the poorer
income quintiles and overestimate for higher income
quintiles. Secondly, consumption expenditure as an alter-
native to income also might overestimate the findings.
Thirdly, indirect costs do not include wage losses due to
the illness, which might underestimate the impact of
healthcare expenditure on the household. Lastly, the data
used for the analyses are self-reported and may be subject
to recall and other biases.
Conclusion
The study shows that a household with a member suffer-
ing from any NCD is exposed to significant financial risks
which lead to catastrophic household expenditure. This
trend is likely to worsen over time due to the rising NCD
epidemic and the ageing population. We strongly advo-
cate for publicly funded risk protection mechanisms tar-
geting the poor. The use of NCD health services from
public facilities results in lower out-of-pocket household
expenses than the use of private services, which warrants
strengthening of public-sector health facilities for better
financial risk protection. Promotion of generic medicines
and better availability and access to essential drugs will
significantly reduce OOP expenditure in public-sector
facilities. NCD prevention and control should be priori-
tised in universal healthcare design and implementation.
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